Cancer du sein: inhibiteurs de l'aromatase en situation adjuvante, un peu, beaucoup ou pas du tout [Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]

Détails

ID Serval
serval:BIB_5CFF674EB18E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Cancer du sein: inhibiteurs de l'aromatase en situation adjuvante, un peu, beaucoup ou pas du tout [Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]
Périodique
Revue Médicale Suisse
Auteur(s)
Perey L., Zaman K.
ISSN
1660-9379
Statut éditorial
Publié
Date de publication
2007
Volume
3
Numéro
130
Pages
2406-2412
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Several large randomized trials showed that tamoxifen alone is no more the standard adjuvant hormonal therapy for menopausal patients. Aromatase inhibitors, given upfront or sequentially after tamoxifen, confirmed their efficacy by improving disease free survival, risk of distant metastasis and overall survival in some situations or subgroups of patients. These drugs are usually well tolerated, but they clearly increase bone mineral density loss as well as the risk of fractures and their long term safety on the cardio-vascular system needs to be followed. Thus, even if the role of the aromatase inhibitors is now evident in the adjuvant therapy of postmenopausal women the benefice/risk ratio should be carefully evaluated for each patient.
Mots-clé
Aromatase Inhibitors, Breast Neoplasms, Chemotherapy, Adjuvant, Clinical Trials as Topic, Female, Humans, Postmenopause
Pubmed
Création de la notice
12/03/2009 15:38
Dernière modification de la notice
20/08/2019 15:15
Données d'usage